Yes. Both. Under the legislation, Canada's Medical Technology Companies and the Canadian Generic Pharmaceutical Association are required to do that.
Let me continue in English.
By law, we've always been required to report adverse events. We have safety studies in the clinical phase and in the regulatory approval phase. We follow good clinical practices and good research practices. Health Canada and the FDA have reciprocal abilities to do good manufacturing inspections of our facilities. Then, in a post-approval world, we have adverse event reporting, risk management plans that continue to be updated, post-market surveillance that either the manufacturers undertake on their accord or regulators order—they both work—and label updates and safety communication, which are some of the things we've already pointed to.